TradingView
JetEquities
19 dic 2019 17:56
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxi
Long
NASDAQ:ATOS
30
Atossa Therapeutics, Inc.
NASDAQ
Descrizione
⋅
19 dic 2019 17:56
ATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
Beyond Technical Analysis
Altro